Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Boehringer Ingelheim | INDUSTRY |
This is a prospective multicenter study in southern Belgium to determine the prevalence and incidence of interstitial lung disease in patients with rheumatoid arthritis (RA).
This is a prospective multi-centric longitudinal study of the prevalence and incidence of pulmonary diseases in patients with RA.
During one year, patients with a RA diagnosis (according to the criteria of the American Society of Rheumatology) in the south of Belgium will be enrolled on a voluntary basis. If available, data including quality of life and symptoms questionnaires, medical examinations, 6-minute walk-tests, pulmonary function tests and chest CT will be collected during two years.
Furthermore, patients could be included (if available data) in two additional sub-cohorts:
Due to a non-specific and poor clinical expression at beginning, there is currently an under-diagnosis of rheumatoid arthritis associated-interstitial lung disease (RA-ILD) at an early stage and we assume that an annual pneumological follow-up, search of early biomarkers and a radiomic approach of RA patients will overcome this issue. This should lead to a better follow-up and management (including the use of anti-fibrotic therapies in the future) of these patients and ultimately to a decrease in morbidity and mortality.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| General cohort | |||
| RAIDbio | Sub-cohort studying biomarkers: volatile organic compounds, induced sputum and blood biomarkers | ||
| RAIDomix | Sub-cohort studying radiomic patterns (based on high resolution computed tomography of the chest) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence and incidence | To determine real-life prevalence and incidence of lung diseases in all patients with RA in South of Belgium | 2-5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Early diagnosis | To diagnose RA-ILD at an earlier stage | 2-5 years |
| Morbidty/mortality | To decrease the morbidity and mortality associated with RA-ILD |
Not provided
Inclusion Criteria:
Exclusion Criteria: none
Not provided
Not provided
Not provided
Not provided
Patients with rheumatoid arthritis visiting their rheumatologist in South of Belgium and willing to participate
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julien Guiot, PhD | Contact | 00324/323 7881 | j.guiot@chuliege.be | |
| Anna Denis, MD | Contact | 00324/323 7881 | anna.denis@chulige.be |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Universitaire de Liege | Recruiting | Liège | 4000 | Belgium |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| D017563 | Lung Diseases, Interstitial |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2-5 years |
| Biomarkers | To identify specific early biomarkers of RA-ILD | 2-5 years |
| Radiomics | To evaluate the prognosis value of radiomics approach in RA-ILD | 2-5 years |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |